- Coordinator
- Sorbonne Universite, France
- Runs
- 1 June 2023 to 31 May 2028
- Status
- Running
- EU funding
- €5.6m
- Total cost
- €5.6m
- Partners
- 10 organisations in 6 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101080897
What the project is doing
In the project's own words, from its summary on CORDIS.
As major players in the regulation of immune responses, regulatory T cells (Tregs) are important therapeutic targets for autoimmune and inflammatory diseases. Interleukin-2 (IL-2) used at low doses (IL-2LD) stimulate and expand Tregs in vivo. While 1st-generation native IL-2LD are currently under extensive clinical evaluation, pharmaceutical companies are developing 2nd-generation IL-2 muteins with improved half-life and activity.
We aim to develop 3rd-generation IL-2 specifically targeting inflammatory sites (IL-2IT) by using antibodies (Abs) against oxidation specific epitopes (OSE) that are both universal markers and mediators of inflammation. IL-2-OSE-Ab fusion proteins should allow dampening of local inflammation by a double-hit mechanism involving Ab neutralization of pro-inflammatory OSE and IL-2 stimulation of Tregs. As a proof of concept, we designed a first IL-2IT in which an IL-2N88R mutein is fused to an scFv from a prototypic anti-OSE Ab.
This IL-2IT (i) binds to IL-2 receptors and OSE, (ii) has an extended half-life and (iii) superior therapeutic efficacy compared to native IL-2 in mice. Our general objectives are to design an optimized IL-2IT by testing combinations of different anti-OSE Ab with IL-2 and IL-2 muteins, and to complete its preclinical development in mice and macaques. We will validate the use of IL-2IT in cardiovascular diseases (CVD), i.e. atherosclerosis, vasculitis, myocardial infarction and SLE-associated CVD, as these conditions have been shown to be improved by Treg infusions, native IL-2 and OSE-Abs in mice.
Carried by leading experts in the use IL-2, OSE-Abs, models of CVD, and clinical trials with native IL-2, the successful validation of an IL-2IT will open a new era for highly selective and effective immunotherapies based on Treg stimulation for diseases that represent a leading cause of death and morbidity. Furthermore, it will validate the broader concept of targeting any therapeutic molecule to inflammatory sites.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Sorbonne Universite | Paris | France | Coordinator |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Universitaet Zu Luebeck | Lubeck | Germany | Third party |
| Universitatsklinikum Schleswig-Holstein | Lübeck | Germany | Participant |
| Icosagen Cell Factory Ou | Kambja Vald | Estonia | Participant |
| Commissariat a L Energie Atomique Et Aux Energies Alternatives | Paris | France | Participant |
| Iltoo Pharma | Paris | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Universita Degli Studi Di Trieste | Trieste | Italy | Participant |
| King's College London | London | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI